Pfizer is expanding commercialization of OXECTA (oxycodone HCl) Tablets CII to health care providers in 4Q13. Acura Pharmaceuticals, Inc. has exclusively licensed its AVERSION Technology to Pfizer in the U.S., Canada and Mexico for use in OXECTA and receives royalties ranging from 5% to 25% on sales.   “We are pleased Pfizer is advancing the commercialization plan for OXECTA,” said Bob Jones, president and chief executive officer of Acura Pharmaceuticals....